Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors

Breast Cancer Research

Volumn 15, Issue 3, 2013, Pages

  Wiebe, John P ^a   Zhang, Guihua ^a,b   Welch, Ian ^a   Cadieux Pitre, Heather Anne T ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

3 dihydroprogesterone; 5 dihydroprogesterone; Biomarkers; Breast cancer; ER PR negative breast cancers; Hormonal control; Microenvironment; Normalcy; Progesterone metabolites; Tumor promoter and suppressor hormones; Tumorigenesis

Indexed keywords

3 ALPHA DIHYDROPROGESTERONE; 5ALPHA PREGNANE 3,20 DIONE; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; 20ALPHA DIHYDROPROGESTERONE; 3-HYDROXYPREGN-4-EN-20-ONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXPERIMENTAL RABBIT; FEMALE; HISTOPATHOLOGY; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; MOUSE; NONHUMAN; RADIOIMMUNOASSAY; SERUM; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG SCREENING; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR VOLUME;

20-ALPHA-DIHYDROPROGESTERONE; 5-ALPHA-DIHYDROPROGESTERONE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE, INBRED NOD; MICE, SCID; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877247538     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3422     Document Type: Article

References (43)

1. American Cancer Society Global Cancer Facts & Figures 2011, Atlanta, American Cancer Society, 2, American Cancer Society., http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/document/acsp-027766.pdf
2. Key TJ, Pike MC. The role of estrogens and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988, 24:29-43. 10.1016/0277-5379(88)90173-3, 3276531.
3. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000, 21:427-433. 10.1093/carcin/21.3.427, 10688862.
4. McGuire WL, Osborne CK, Clark GM, Knight WA. Steroid hormone receptors and carcinoma of the breast. Am J Physiol 1982, 243:E99-E102.
5. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K. Hormone receptors as prognostic factors in female breast cancer. Ann Med 1991, 6:643-648.
6. Howat JMT, Harris M, Swindell R, Barnes DM. The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 1985, 51:263-270. 10.1038/bjc.1985.38, 1977040, 3966982.
7. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlböck M, Jakesz R. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 2003, 10:91-98. 10.1677/erc.0.0100091, 12653672.
8. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008, 10:R89. 10.1186/bcr2187, 2614526, 18947395.
9. Robinson GW, Hennighausen L, Johnson PF. Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev 2000, 14:889-894.
10. Paone JF, Abeloff MD, Ettinger DS, Arnold EA, Baker PR. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast. Surg Gynecol Obstet 1981, 152:70-74.
11. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Béraud T, Gómez F. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women: clinical correlation on 547 patients. Cancer 1986, 57:1171-1180. 10.1002/1097-0142(19860315)57:6<1171::AID-CNCR2820570618>3.0.CO;2-X, 3943040.
12. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988, 7:1076-1087.
13. Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer data bases. J Clin Oncol 2003, 21:1973-1979. 10.1200/JCO.2003.09.099, 12743151.
14. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6. doi:10.1186/bcr 1639, 10.1186/bcr1639, 1851385, 17239243.
15. Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA, Seachrist JL. The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res 2000, 60:936-943.
16. Wiebe JP, Lewis MJ. Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid oxidoreductase and 3α(β)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer 2003, 3:9. 10.1186/1471-2407-3-9, 154104, 12659654.
17. Wiebe JP. Progesterone metabolites in breast cancer. Endocr Relat Cancer 2006, 13:717-738. 10.1677/erc.1.01010, 16954427.
18. Wiebe JP, Beausoleil M, Zhang G, Cialacu V. Opposing actions of the progesterone metabolites, 5α-dihydroprogesterone (5αP) and 3α-dihydroprogesterone (3αHP) on mitosis, apoptosis, and expression of BCL-2, Bax and p21 in human breast cell lines. J Steroid Biochem Mol Biol 2010, 118:125-132. 10.1016/j.jsbmb.2009.11.005, 19931389.
19. Weiler PJ, Wiebe JP. Plasma membrane receptors for the cancer-regulating progesterone metabolites, 5α-pregnane-3,20-dione and 3α-hydroxy-4-pregnen-20-one in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2000, 272:731-737. 10.1006/bbrc.2000.2847, 10860824.
20. Wiebe JP, Barr KJ, Buckingham KD. A radioimmunoassay for the regulatory allylic steroid, 3α-hydroxy-4-pregnen-20-one (3αHP). J Steroid Biochem Mol Biol 1991, 38:505-512. 10.1016/0960-0760(91)90339-7, 2031864.
21. Erlanger BF, Borek F, Beiser SM, Lieberman S. Steroid-protein conjugates: preparation and characterization of conjugates of bovine serum albumin with testosterone and with cortisone. J Biol Chem 1957, 228:713-727.
22. Naar J, Branaa P, Chinain M, Pauillac S. An improved method for the microscale preparation and characterization of hapten-protein conjugates: the use of cholesterol as a model for nonchromophore hydroxylated haptens. Bioconjugate Chem 1999, 10:1143-1149.
23. Wiebe JP, Deline C, Buckingham KD, Dave V, Stothers JB. Synthesis of the allylic gonadal steroids, 3α-hydroxy-4-pregnen-20-one and 3α-hydroxy-4-androsten-17-one, and of 3α-hydroxy-5α-pregnan-20-one. Steroids 1985, 45:39-51. 10.1016/0039-128X(85)90064-9, 4089911.
24. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990, 50:717-721.
25. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980, 46:2884-2888. 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U, 7448733.
26. Ciocca DR, Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 2000, 13:1-10. 10.1385/ENDO:13:1:1, 11051041.
27. Jiang S-Y, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591. 10.1093/jnci/84.8.580, 1556769.
28. Lin VCL, Eng AS, Hen NE, Ng EHL, Chowdhury SH. Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin Cancer Res 2001, 7:2880-2886.
29. Pawlak KJ, Zhang G, Wiebe JP. Membrane 5α-pregnane-3,20-dione (5αP) receptors in MCF-7 and MCF-10A breast cancer cells are up-regulated by estradiol and 5αP and down-regulated by the progesterone metabolites, 3α-dihydroprogesterone and 20α-dihydroprogesterone, with associated changes in cell proliferation and detachment. J Steroid Biochem Mol Biol 2005, 97:278-288. 10.1016/j.jsbmb.2005.05.014, 16154741.
30. Wiebe JP, Lewis MJ, Cialacu V, Pawlak KJ, Zhang G. The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J Steroid Biochem Mol Biol 2005, 93:201-208. 10.1016/j.jsbmb.2004.12.003, 15860263.
31. Wiebe JP, Muzia D. The endogenous progesterone metabolite, 5α-pregnane-3,20-dione, decreases cell-substrate attachment, adhesion plaques, vinculin expression, and polymerized F-actin in MCF-7 breast cancer cells. Endocrine 2001, 16:7-14. 10.1385/ENDO:16:1:07, 11822829.
32. Beck CA, Wolfe M, Murphy LD, Wiebe JP. Acute, nongenomic actions of the neuroactive gonadal steroid, 3α-hydroxy-4-pregnen-20-one (3αHP), on FSH release in perifused rat anterior pituitary cells. Endocrine 1997, 6:221-229. 10.1007/BF02820496, 9368676.
33. Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004, 4:27. 10.1186/1471-2407-4-27, 459223, 15212687.
34. Abul-Hajj YJ, Iverson R, Kiang DT. Metabolism of pregnenolone by human breast cancer: evidence for 17alpha-hydroxylase and 17,20-lyase. Steroids 1979, 34:817-827. 10.1016/0039-128X(79)90094-1, 161434.
35. Gunasegaram R, Peh KL, Loganath A, Ratnam SS. Expression of 3β-hydroxysteroid dehydrogenase-5,4-en isomerase activity by infiltrating ductal human breast carcinoma in vitro. Breast Cancer Res Treat 1998, 50:117-123. 10.1023/A:1006009031839, 9822216.
36. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988, 240:177-184. 10.1126/science.2451290, 2451290.
37. Kenny PA, Bissell MJ. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 2003, 107:688-695. 10.1002/ijc.11491, 2933180, 14566816.
38. Hayashi S-I, Yamaguchi Y. Estrogen signaling pathway and hormone therapy. Breast Cancer 2008, 15:256-261. 10.1007/s12282-008-0070-z, 18818989.
39. Hu M, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Eur J Cancer 2008, 44:2760-2765. 10.1016/j.ejca.2008.09.038, 2729518, 19026532.
40. Wilson C, Holen I, Coleman RE. Seed, soil and secreted hormones: potential interactions by breast cancer cells with their endocrine/paracrine microenvironments and implications for treatment with bisphosphonates. Cancer Treat Rev 2012, 38:877-889. 10.1016/j.ctrv.2012.02.007, 22398187.
41. Fuqua SA. Where is the lesion in hormone-independent breast cancer?. J Natl Cancer Inst 1992, 84:554-555. Bethesda, 10.1093/jnci/84.8.554, 1556761.
42. Murphy LC. Mechanisms of hormone independence in human breast cancer. In Vivo 1998, 12:95-106.
43. Pawlak KJ, Wiebe JP. Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites. J Steroid Biochem Mol Biol 2007, 107:172-179. 10.1016/j.jsbmb.2007.05.030, 17683929.